HBM Holdings Investor Relations Material

HBM Holdings Limited is a China-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative antibody therapeutics. The company utilizes its proprietary antibody technology platforms to develop a pipeline of monoclonal antibodies targeting various diseases, including cancer and autoimmune disorders. HBM Holdings conducts research and clinical development independently and through strategic partnerships in both domestic and international markets. The company is headquartered in Shanghai, China, and its shares are listed on the HKEX.